| I-05 Ahmad Abuhelwa Population pharmacokinetic and pharmacodynamic modelling of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression Wednesday 09:50-11:15 |
| I-12 Joachim Almquist Estimation of equipotent doses of the oral selective glucocorticoid receptor modulator (oSGRM) AZD9567 and prednisolone based on ex vivo TNFa inhibition after LPS stimulation Wednesday 09:50-11:15 |
| I-13 Jokha AL-Qassabi Predicting the Fraction Unbound (fu) and Plasma Drug Clearance Based on Known Changes in Albumin and Alpha1-Acid Glycoprotein Levels at Varying Degrees of Renal Impairment Wednesday 09:50-11:15 |
| I-16 Million Arefayene Population Pharmacokinetics (PK) and pharmacodynamics (PD) Modeling of anti-avß6 integrin Antibody (BG00011) Wednesday 09:50-11:15 |
| I-21 Ioanna Athanasiadou Hyperhydration effect on pharmacokinetic parameters of recombinant human erythropoietin in urine and serum doping control analysis Wednesday 09:50-11:15 |
| I-29 Violeta Balbas-Martinez Quantitative Systems Pharmacology model for the key Interleukins involved in Crohn's Disease Wednesday 09:50-11:15 |
| I-35 Francesco Bellanti Application of Model-Based Meta-Analysis to evaluate the relationship between early biomarker to late stage clinical endpoints for the development of anti-asthmatic drugs Wednesday 09:50-11:15 |
| I-36 Amina Bensalem Nonlinear pharmacokinetics and concentration-effect relationship of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis Wednesday 09:50-11:15 |
| I-39 Martin Bergstrand Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling Wednesday 09:50-11:15 |
| I-40 Jan Berkhout Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia Wednesday 09:50-11:15 |
| I-57 Antonio Cabal Using multiscale mechanism based mathematical modeling to address many of the challenges associated with the estimation of local lung concentration after inhaled drug delivery Wednesday 09:50-11:15 |
| I-59 Elisa Calvier Alirocumab population pharmacokinetics in Chinese patients using priors Wednesday 09:50-11:15 |
| I-83 Eva Maria del Amo Paez Pharmacokinetics after intravitreal injection of a new anti-angiogenic therapeutic compound in rabbit eyes Wednesday 09:50-11:15 |
| I-84 Francesca Del Bene Intratympanic drug administration: a challenge for PK modelling Wednesday 09:50-11:15 |
| II-01 Åsa Kragh Population pharmacokinetic analysis of PT010, an inhaled triple fixed-dose combination product, in patients with chronic obstructive pulmonary disease Wednesday 15:10-16:40 |
| II-09 Jacob Leander Development of a population pharmacokinetic model of verinurad used for simulations of various dosing scenarios in different populations Wednesday 15:10-16:40 |
| II-11 Woo Yul Lee Population pharmacokinetics of recombinant coagulation factor VIII in Korean hemophila A patients Wednesday 15:10-16:40 |
| II-12 Soyoung Lee Population Pharmacokinetic Analysis for Novel Acid Pump Antagonist DWP14012 Wednesday 15:10-16:40 |
| II-19 Patrick Lilienthal Mathematical modeling of RBC count dynamics after blood loss Wednesday 15:10-16:40 |
| II-23 Rasmus Jansson Löfmark Translational pharmacokinetic-pharmacodynamic modelling predicts human exposure target engagement Wednesday 15:10-16:40 |
| II-25 Dominik Lott Prediction of exposure and effect on total lymphocyte count following long-term treatment of healthy subjects and lupus patients with the selective S1P1 receptor modulator cenerimod Wednesday 15:10-16:40 |
| II-26 Qiang Lu Population Pharmacokinetic Meta-Analysis of Dupilumab in Adult Atopic Dermatitis Patients, Asthma Patients, and Healthy Subjects Wednesday 15:10-16:40 |
| II-35 Mats Magnusson Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis Wednesday 15:10-16:40 |
| II-43 Christophe Meille Combining BLRM and safety PKPD models to improve decision making in a phase I dose escalation study: case study of PCA062, an antibody drug conjugate targeting P-Cadherin Wednesday 15:10-16:40 |
| II-49 Iris Minichmayr Impact of genetic variants of UGT1A1 on myelosuppression during irinotecan therapy Wednesday 15:10-16:40 |
| II-52 Camille Riff Population Pharmacokinetics of Rituximab in patients with Chronic Lymphocytic Leukemia Wednesday 15:10-16:40 |
| II-56 Ricardo Nalda-Molina Evaluation of the predictive performance and the model adequacy of four population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease. Wednesday 15:10-16:40 |
| II-57 Srividya Neelakantan Population Pharmacokinetic/Pharmacodynamic Modeling of PF-06480605, an Anti-TL1A Antibody, in Healthy Subjects and Ulcerative Colitis Patients Wednesday 15:10-16:40 |
| II-63 Boram Ohk Population pharmacokinetic analysis of tacrolimus: The role of integrative pharmacogenetics and pharmacometabolomics Wednesday 15:10-16:40 |
| II-65 Sean Oosterholt Model-based optimisation of N-acetylcysteine for the treatment of paracetamol overdose Wednesday 15:10-16:40 |
| II-69 Robert Palmér A novel joint modelling approach to estimating treatment effects on COPD exacerbations in the presence of differential discontinuations Wednesday 15:10-16:40 |
| II-77 Philippe Pierrillas PK-PD modelling of C4 concentrations after administration of a FXR agonist in healthy volunteers and Hepatitis B patients Wednesday 15:10-16:40 |
| II-79 Vikram Prabhakar QSP Model of Rheumatoid Arthritis, capturing range of clinical responses to Methotrexate and anti-TNF-a therapies Wednesday 15:10-16:40 |
| II-86 Michael Reed Evaluation of competitive differentiation of novel therapies and the impact of patient variability on efficacy in a psoriasis QSP platform Wednesday 15:10-16:40 |
| II-88 Isabel Reinecke Levonorgestrel-Containing Contraceptives: Comparison of Daily Doses and Exposure for Various Routes of Administration by an Integrated Population Pharmacokinetic Analysis Wednesday 15:10-16:40 |
| II-89 Dinko Rekic Higher Febuxostat Exposure observed in Japanese Compared to Caucasian Subjects Independent of Bodyweight Wednesday 15:10-16:40 |
| III-08 Ryosuke Shimizu Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for thrombocytopenia Thursday 09:55-11:20 |
| III-28 Felix Stader Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving age-related changes in drug exposure in the elderly Thursday 09:55-11:20 |
| III-32 Sabine Stuebler Systems biology model of the mucosal immune system Thursday 09:55-11:20 |
| III-41 Mita Thapar Population pharmacokinetic analysis of MSB11022 following administration in healthy subjects and rheumatoid arthritis patients. Thursday 09:55-11:20 |
| III-50 David Uster Predictive performance of population pharmacokinetic models for Bayesian forecasting of coagulation factor VIII in hemophilia A Thursday 09:55-11:20 |
| III-60 Diego Vera Pharmacokinetic-Pharmacodynamic model for Acute Intermittent Porphyria in porphyric mice treated with a new recombinant PBGD protein Thursday 09:55-11:20 |
| III-64 Ulrika Wählby Hamrén Longitudinal FEV1 and exacerbation risk in COPD: Quantifying the association using joint modelling Thursday 09:55-11:20 |
| III-68 Linda Wanika Investigating the relationship between Lactate Dehydrogenase and the occurrence of Chronic Lower Respiratory Diseases Thursday 09:55-11:20 |
| III-90 Tom Zwart Population pharmacokinetics and limited sampling of iohexol as a renal function marker Thursday 09:55-11:20 |
| IV-05 Vincent Duval A continuous-time Markov model (CTMM) for investigator’s global assessment (IGA) score in moderate-to-severe atopic dermatitis treated with subcutaneous nemolizumab. Thursday 15:25-16:50 |
| IV-13 Anam Fayyaz Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes Thursday 15:25-16:50 |
| IV-14 Anam Fayyaz Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes Thursday 15:25-16:50 |
| IV-19 Yu Fu Hemodynamic systems model to characterize cardiovascular drug effects Thursday 15:25-16:50 |
| IV-22 Masato Fukae Population pharmacokinetic modeling of esaxerenone: a novel nonsteroidal mineralocorticoid receptor blocker Thursday 15:25-16:50 |
| IV-28 Eva Germovsek A time-to-event model relating integrated craving to risk of smoking relapse across different nicotine replacement therapy formulations Thursday 15:25-16:50 |
| IV-32 Ignacio Gonzalez-Garcia Pharmacokinetic/Pharmacodynamic Modelling of in vivo IL-13 Modulation by a monoclonal antibody (MEDI7836) Thursday 15:25-16:50 |
| IV-40 Stefanie Hamacher Population pharmacokinetics of cannabidiol in healthy subjects Thursday 15:25-16:50 |
| IV-53 Chih-hsuan Hsin Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics of digoxin in healthy Caucasian subjects Thursday 15:25-16:50 |
| IV-56 Eman Ibrahim Obesity and NAFLD activity score increase rate of fibrosis progression in a continuous-time Markov modelling of fibrosis progression in a long-term follow-up biopsy NAFLD cohort. Thursday 15:25-16:50 |
| IV-62 Petra Jauslin Modeling bounded scales for evaluation of treatment response to subcutaneous nemolizumab in moderate to severe atopic dermatitis Thursday 15:25-16:50 |
| IV-70 Wannee kantasiripitak A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis Thursday 15:25-16:50 |
| IV-80 Zackary Kenz Inflammation and Fibrosis in Nonalcoloholic Steatohepatitis (NASH) Characterized by a Mathematical Model Thursday 15:25-16:50 |
| IV-82 NaYoung Kim Development of predictive model for acute kidney injury after minimally invasive partial nephrectomy Thursday 15:25-16:50 |
